AngioJet Thrombectomy System Aids Cost Saving In DES Procedures – Possis
This article was originally published in The Gray Sheet
Executive Summary
The advent of drug-eluting stents (DES) is benefiting sales of Possis Medical's AngioJet Rheolytic thrombectomy system, the firm says
You may also be interested in...
Possis RX Heart Catheter Approval, Anticipation Of AiMI Data Boost Stock
Possis Medical's receipt of PMA supplement approval for coronary use of its AngioJet Rheolytic XMI-RX rapid exchange thrombectomy catheter helped propel the firm's stock ahead 12% in May to $28.49
Possis RX Heart Catheter Approval, Anticipation Of AiMI Data Boost Stock
Possis Medical's receipt of PMA supplement approval for coronary use of its AngioJet Rheolytic XMI-RX rapid exchange thrombectomy catheter helped propel the firm's stock ahead 12% in May to $28.49
Possis Medical AngioJet XMI-RX
Rapid-exchange version of the firm's XMI Rheolytic thrombectomy catheter is approved via PMA supplement for coronary use with the firm's AngioJet system. Previously approved for peripheral use, XMI-RX also has received a CE mark for coronary use in Europe, clearing the way for its launch at the Paris Course on Revascularization meeting May 25-28. The firm expects the catheter to boost AngioJet market penetration (1"The Gray Sheet" Feb. 23, 2004, p. 21)...